Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Launched by AMGEN · Jun 16, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medicine called maridebart cafraglutide to see if it can help people who have heart failure with either preserved or mildly reduced heart function, and who are also obese. The main goal is to find out if adding this medicine to the usual treatments can reduce serious heart failure problems like hospital visits, emergency care, or heart-related deaths, and if it can help improve symptoms of heart failure.

People eligible to join this study are adults with a body mass index (BMI) of 30 or higher, which means they are considered obese. They must have had heart failure for at least a month, with a specific level of heart function that is not severely reduced. They should already be receiving standard heart failure treatments and show signs of heart stress based on certain tests. The study will be conducted in two parts, with participants receiving either the study medicine or a placebo without knowing which one, followed by a period where everyone can receive the medicine. If you join, you can expect regular check-ups and monitoring over time to track your heart health and any side effects. This trial is not yet recruiting, and certain health conditions or recent serious heart problems may mean someone cannot participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years.
• • BMI ≥ 30 kg/m\^2.
• • HF diagnosed for at least 30 days before screening with New York Heart Association (NYHA) Class II-IV.
• • Managed with HF standard of care therapies.
• • Left ventricular ejection fraction (LVEF) of \> 40%.
• • Elevated NT-proBNP.
• * Participants must have at least one of the following:
• • 1. Structural heart disease OR
• • 2. Documented hospitalization with a primary diagnosis of decompensated HF within 12 months before randomization OR
• • 3. Evidence of elevated filling pressures within 12 months before randomization.
• Exclusion Criteria:
• • History of any of the following within 60 days before screening: Type I (spontaneous) MI, valvular replacement or repair, coronary revascularization, coronary artery bypass graft surgery or other major cardiovascular surgery, stroke.
• • HF due to: hypertrophic cardiomyopathy, infiltrative cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, arrhythmogenic right ventricular or left ventricular cardiomyopathy/dysplasia, or uncorrected primary valvular heart disease, or clinically significant congenital heart disease.
• • Any lifetime history of LVEF ≤ 40%.
• • Currently hospitalized with acute decompensated HF or hospitalization with a primary diagnosis of decompensated HF within 30 days before screening.
• • Type 1 diabetes mellitus, or any type of diabetes with the exception of T2DM or history of gestational diabetes.
• * For participants with a prior diagnosis of T2DM at screening:
• • 1. HbA1c \> 10.0%
• • 2. Uncontrolled diabetes requiring immediate therapy
• • 3. History of diabetic ketoacidosis or hyperosmolar state/coma
• • 4. One or more episodes of severe hypoglycemia within 6 months before screening and/or history of hypoglycemia unawareness
• • 5. History of proliferative diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy.
• • SBP ≥ 180 mmHg , or on three or more blood pressure-lowering drugs with a SBP \> 160 mmHg.
• • History of chronic pancreatitis or acute pancreatitis in the 180 days before screening.
• • Family (or personal) history of medullary thyroid carcinoma or MEN-2.
• • eGFR \< 20 mL/min/1.73 m\^2 (CKD-EPI creatinine (Cr)-cystatin C equation) or receiving dialysis at screening.
• • Calcitonin ≥ 50 ng/L (pg/mL) at screening.
• • Acute or chronic hepatitis.
• * Any of the following psychiatric history:
• • 1. History of unstable major depressive disorder or other severe psychiatric disorder within 2 years before screening
• • 2. Lifetime history of suicide attempt
• • 3. History of non-suicidal self-injury within 5 years before screening.
• • History of any other condition that, in the opinion of the investigator, may preclude the participant from following the protocol and completing the study.
• • Use of any glucagon-like peptide 1 receptor agonist (GLP-1 RA), glucose-dependent insulinotropic polypeptide (GIP) agonists or antagonists, or amylin analogs within 90 days before randomization or planned use during the conduct of the study.